

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

FIG. 1





FIG. 2



FIGS. 3A-3E





FIG. 4A



**FIG. 4B**

<b>Treatment</b>	<b># of mice with complete tumor eradication after therapy</b>
L1C2 control + no treatment	0/8
L1C2 + intratumoral $10^8$ pfu Ad-CV	0/8
L1C2 + intratumoral $10^8$ pfu Ad-SLC	5/8

**FIG. 5A**  
**Table 1A**

Groups	PGE2	VEGF	IFN- $\gamma$	GM-CSF	IL-10	IL-12	TGF- $\beta$	MIG	IP-10
3LL + diluent	28.510 $\pm$ 400	757 $\pm$ 26	104 $\pm$ 15	<5	244 $\pm$ 6	24 $\pm$ 6	5.820 $\pm$ 578	1.000 $\pm$ 200	15.100 $\pm$ 1.100
3LL + SLC	8.737 $\pm$ 210*	222 $\pm$ 34*	549 $\pm$ 16*	56 $\pm$ 11	42 $\pm$ 13*	42 $\pm$ 1*	2.473 $\pm$ 26*	6.600 $\pm$ 100*	39.400 $\pm$ 2.300*

\* $p < 0.01$  compared with diluent-treated tumor-bearing mice.  $n = 6$  mice/group.

**FIG. 5B**  
**Table 1B**

Group	PGE-2	VEGF	IL-10	IFN- $\gamma$	GM-CSF	IL-12	MIG	IP-10	TGF- $\beta$
Lung									
CC-10 + diluent	12419 $\pm$ 384	980 $\pm$ 38	213 $\pm$ 11	26 $\pm$ 5	74 $\pm$ 5	110 $\pm$ 8	47.8 $\pm$ 5	108 $\pm$ 6	281 $\pm$ 0
CC-10 + SLC	11945 $\pm$ 208	222 $\pm$ 53 <sup>a</sup>	239 $\pm$ 20	4174 $\pm$ 26 <sup>a</sup>	611 $\pm$ 11 <sup>a</sup>	235 $\pm$ 15 <sup>a</sup>	98.4 $\pm$ 4	187 $\pm$ 2 <sup>a</sup>	154 $\pm$ 15 <sup>a</sup>
FVB control	6023 $\pm$ 40	222 $\pm$ 53	129 $\pm$ 8	122 $\pm$ 28	73 $\pm$ 3	167 $\pm$ 7	72.3 $\pm$ 6	57 $\pm$ 5	118 $\pm$ 9
Splenocytes									
FVB control mice	72 $\pm$ 2	107 $\pm$ 36	85 $\pm$ 0	101 $\pm$ 24	44 $\pm$ 1	66 $\pm$ 8	89	96 $\pm$ 5	20 $\pm$ 2
Diluent-treated CC-10	643 $\pm$ 51	267 $\pm$ 14	87 $\pm$ 11	106 $\pm$ 3	45 $\pm$ 3	67 $\pm$ 6	42	63 $\pm$ 3	<15
SLC-treated CC-10	44 $\pm$ 10 <sup>a</sup>	13 $\pm$ 1 <sup>a</sup>	84 $\pm$ 11	107 $\pm$ 9	110 $\pm$ 4 <sup>a</sup>	137 $\pm$ 5 <sup>a</sup>	142 <sup>a</sup>	216 $\pm$ 5 <sup>a</sup>	17 $\pm$ 5
Lymph node									
FVB control mice	148 $\pm$ 3	204 $\pm$ 18	78 $\pm$ 6	98 $\pm$ 23	65 $\pm$ 2	195 $\pm$ 5	70	<15	102 $\pm$ 4
Diluent-treated CC-10	94 $\pm$ 3	142 $\pm$ 12	81 $\pm$ 4	89 $\pm$ 9	42 $\pm$ 2	95 $\pm$ 10	46	43 $\pm$ 3	139 $\pm$ 6
SLC-treated CC-10	113 $\pm$ 4	221 $\pm$ 32	86 $\pm$ 20	192 $\pm$ 8 <sup>a</sup>	44 $\pm$ 3	233 $\pm$ 6 <sup>a</sup>	106 <sup>a</sup>	100 $\pm$ 2 <sup>a</sup>	89 $\pm$ 7 <sup>a</sup>

<sup>a</sup> $p < 0.01$  compared to diluent-treated CC-10 tumor-bearing mice.

FIG. 6A  
TABLE 2A

		CD4				CD8				CD11c + DEC205	
		IFN- $\gamma$		GM-CSF		IFN- $\gamma$		GM-CSF			
Groups		%	MCF	%	MCF	%	MCF	%	MCF	%	MCF
<i>Tumor</i>											
3LL		3.6	193	4.8	31	1.9	389	1.7	44	4	103
3LL + SLC		7.4*	187	5.3	52*	3.2*	306	2.7*	47	13*	108
LN											
3LL		0.9	86	0.8	50	0.9	131	0.5	78	32	79
3LL + SLC		1.7*	340*	1.2*	181*	1.7*	181	1.3*	107*	40*	118*

\*  $p < 0.01$  ( $n = 6$  mice/group)

**FIG. 6B**  
**TABLE 2B**

Groups	CD4 <sup>+</sup>				CD8 <sup>+</sup>				CD11c+DEC205			
	IFN- $\gamma$		GMF-CSF		IFN- $\gamma$		GM-CSF					
	%	MCF	%	MCF	%	MCF	%	MCF	%	MCF	%	MCF(DEC205)
<b>Tumor</b>												
CC-10 + diluent	2	124	2.4	38	2	307	1.5	53	3.2			121
CC-10 + SLC	5 <sup>a</sup>	187	5.2 <sup>a</sup>	89	5.3 <sup>a</sup>	311	3.7	89	11.7 <sup>a</sup>			132
<b>Lymph node</b>												
CC-10 + diluent	3.2	154	3.3	80	1	200	1.3	52	5.3			54.4
CC-10 + SLC	6.8 <sup>a</sup>	173	5.7 <sup>a</sup>	102	6.8 <sup>a</sup>	244.9 <sup>a</sup>	3 <sup>a</sup>	55	12.7 <sup>a</sup>			79
<b>Spleen</b>												
CC-10 + diluent	3.9	163	1.5	60	1.1	311	0.7	88	5.9			82
CC-10 + SLC	4.7	206 <sup>a</sup>	1.6	168 <sup>a</sup>	3.8 <sup>a</sup>	352	2.1 <sup>a</sup>	54	11.4 <sup>a</sup>			101

<sup>a</sup>  $P < 0.01$ ,  $n$  = six mice/group. For DC staining, MCF (mean channel fluorescence) is noted for DEC205. Experiments were repeated twice.



**FIG. 7A**  
**TABLE 3A**

Group	IFN- $\gamma$	GM-CSF	IL-10	IL-12
<b>Splenocytes</b>				
Mice without tumor, constitutive	220=30	0	0	78=1
Stimulated with 3LL	85 $\pm$ 19	37=2	0	16=3
Diluent-treated, constitutive	117 $\pm$ 41	0	18 $\pm$ 1	60=12
Stimulated with 3LL	97 $\pm$ 13	23 $\pm$ 9*	1566 $\pm$ 93	51=1
SLC-treated, constitutive	113 $\pm$ 21	0	16 $\pm$ 1	111=1
Stimulated with 3LL	2731 $\pm$ 99*	71 $\pm$ 2*	181 $\pm$ 14*	206=7*
<b>Lymph node</b>				
Mice without tumor, constitutive	248 $\pm$ 1	16 $\pm$ 1	0	60=1
Stimulated with 3LL	87 $\pm$ 12	34 $\pm$ 7	0	48=1
Diluent-treated, constitutive	166 $\pm$ 16	16 $\pm$ 1	297 $\pm$ 10	25=1
Stimulated with 3LL	96 $\pm$ 17	52 $\pm$ 8	816 $\pm$ 25	84=6
SLC-treated, constitutive	256 $\pm$ 10	19 $\pm$ 1	0	25=1
Stimulated with 3LL	1242 $\pm$ 270*	49 $\pm$ 6	133 $\pm$ 17*	108=3*

\*  $p < 0.01$  compared with diluent-treated mice and SLC constitutive levels:  $n^4=6$  mice/group.

**FIG. 7B**  
**TABLE 3B**

Group	IFN- $\gamma$	GM-CSF	IL-10
No tumor			
Mice without tumor, constitutive	634 $\pm$ 45	55 $\pm$ 7	32 $\pm$ 4
Stimulated with CC-10 cells	685 $\pm$ 39	87 $\pm$ 5	147 $\pm$ 8
Diluent-treated			
Diluent-treated, constitutive	400 $\pm$ 38	104 $\pm$ 11	78 $\pm$ 2
Stimulated with CC-10 cells	379 $\pm$ 28	132 $\pm$ 5	1000 $\pm$ 69
SLC-treated			
SLC-treated, constitutive	617 $\pm$ 42	185 $\pm$ 3	49 $\pm$ 2
Stimulated with CC-10 cells	2265 $\pm$ 107 <sup>a</sup>	287 $\pm$ 10 <sup>a</sup>	200 $\pm$ 7 <sup>a</sup>